These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 33485761)
1. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage. Grimberg DC; Dudinec J; Shah A; Inman BA Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study. Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006 [TBL] [Abstract][Full Text] [Related]
3. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis. Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493 [TBL] [Abstract][Full Text] [Related]
4. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. Guerrero-Ramos F; González-Padilla DA; González-Díaz A; de la Rosa-Kehrmann F; Rodríguez-Antolín A; Inman BA; Villacampa-Aubá F World J Urol; 2022 Apr; 40(4):999-1004. PubMed ID: 35037963 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study. Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ; Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer. Magalhães JC; Sousa M; Basto R; Fraga T; Gomes I; Fernandes C; Mariano M; Paulo J; Madeira P; Sousa G Cureus; 2023 Sep; 15(9):e45672. PubMed ID: 37745737 [TBL] [Abstract][Full Text] [Related]
8. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder]. Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718 [TBL] [Abstract][Full Text] [Related]
10. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer. Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812 [TBL] [Abstract][Full Text] [Related]
11. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. Mangiarotti B; Trinchieri A; Del Nero A; Montanari E Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434 [TBL] [Abstract][Full Text] [Related]
12. Intravesical electromotive drug administration for non-muscle invasive bladder cancer. Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance. Akbulut F; Pazir Y; Esmeray A; Erbin A; Ozgor F; Sarilar O Urologia; 2023 Nov; 90(4):631-635. PubMed ID: 37470319 [TBL] [Abstract][Full Text] [Related]
14. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907 [TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Hyperthermia Intravesical Chemotherapy in the Treatment of Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis. Duan H; Deng Z; Zou J; Zhang G; Zou X; Xie T Urol Int; 2024; 108(4):322-333. PubMed ID: 38508149 [TBL] [Abstract][Full Text] [Related]
16. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129 [TBL] [Abstract][Full Text] [Related]
19. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445 [TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients. Conroy S; Pang K; Jubber I; Hussain SA; Rosario DJ; Cumberbatch MG; Catto JWF; Noon AP BJUI Compass; 2023 May; 4(3):314-321. PubMed ID: 37025474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]